PURPOSE: Despite improvements in frontline pediatric acute lymphoblastic leukemia (ALL) treatment, relapse remains a concern. Research in adult cancer patients suggests that patient-reported symptoms may predict survival, but the relationship between symptoms and relapse for pediatric ALL has received little attention. METHODS: Pediatric patients with ALL (age 2-18 years) and/or their primary caregivers completed symptom surveys at the end of induction, start of delayed intensification (DI), start of maintenance cycle 1 (MC1), and start of maintenance cycle 2 (MC2). Symptom clusters for co-occurring fatigue, pain, sleep disruptions, and nausea were defined using latent profile analysis. Hazard ratios (HR) and 95% confidence intervals (CI) for the association between symptom clusters, individual symptoms, and subsequent relapse were calculated using multivariable Cox proportional hazards models, adjusting for clinical and demographic factors. RESULTS: Eligible patients (n = 208) were followed an average of 2.6 years for the incidence of relapse (n = 22). Associations between relapse and symptoms were identified for fatigue at DI (HR = 1.83, 95%CI 1.23-2.73) and MC1 (HR = 2.14, 95%CI 1.62-2.84), pain at DI (HR = 1.80, 95%CI 1.19-2.72), nausea at the end of induction (HR = 1.19, 95%CI 1.01-1.39), and sleep disturbances at the end of induction (HR = 2.00, 95%CI 1.11-3.62), DI (HR = 1.73, 95%CI 1.01-2.96), and MC1 (HR = 2.19, 95%CI 1.10-4.35). Symptom clusters comprised of individuals with a higher average symptom burden at DI were significantly (p < 0.05) associated with relapse. CONCLUSION: Patient-reported symptoms may provide prognostic information to aid in the identification of pediatric ALL patients at increased risk of relapse.
PURPOSE: Despite improvements in frontline pediatric acute lymphoblastic leukemia (ALL) treatment, relapse remains a concern. Research in adult cancer patients suggests that patient-reported symptoms may predict survival, but the relationship between symptoms and relapse for pediatric ALL has received little attention. METHODS: Pediatric patients with ALL (age 2-18 years) and/or their primary caregivers completed symptom surveys at the end of induction, start of delayed intensification (DI), start of maintenance cycle 1 (MC1), and start of maintenance cycle 2 (MC2). Symptom clusters for co-occurring fatigue, pain, sleep disruptions, and nausea were defined using latent profile analysis. Hazard ratios (HR) and 95% confidence intervals (CI) for the association between symptom clusters, individual symptoms, and subsequent relapse were calculated using multivariable Cox proportional hazards models, adjusting for clinical and demographic factors. RESULTS: Eligible patients (n = 208) were followed an average of 2.6 years for the incidence of relapse (n = 22). Associations between relapse and symptoms were identified for fatigue at DI (HR = 1.83, 95%CI 1.23-2.73) and MC1 (HR = 2.14, 95%CI 1.62-2.84), pain at DI (HR = 1.80, 95%CI 1.19-2.72), nausea at the end of induction (HR = 1.19, 95%CI 1.01-1.39), and sleep disturbances at the end of induction (HR = 2.00, 95%CI 1.11-3.62), DI (HR = 1.73, 95%CI 1.01-2.96), and MC1 (HR = 2.19, 95%CI 1.10-4.35). Symptom clusters comprised of individuals with a higher average symptom burden at DI were significantly (p < 0.05) associated with relapse. CONCLUSION: Patient-reported symptoms may provide prognostic information to aid in the identification of pediatric ALL patients at increased risk of relapse.
Authors: Gerald Rosen; Anne K Harris; Meixia Liu; Jill Dreyfus; James Krueger; Yoav H Messinger Journal: Sleep Med Date: 2015-02-02 Impact factor: 3.492
Authors: Pamela S Hinds; Jie Yang; Jami S Gattuso; Marilyn Hockenberry; Heather Jones; Sue Zupanec; Chenghong Li; Valerie McLaughlin Crabtree; Belinda N Mandrell; Robert A Schoumacher; Kelly Vallance; Stacy Sanford; Deo Kumar Srivastava Journal: J Pain Symptom Manage Date: 2010-03 Impact factor: 3.612
Authors: Andrea L Cheville; Paul J Novotny; Jeffrey A Sloan; Jeffrey R Basford; Jason A Wampfler; Yolanda I Garces; Aminah Jatoi; Ping Yang Journal: J Pain Symptom Manage Date: 2011-03-12 Impact factor: 3.612
Authors: Marilyn J Hockenberry; Mary C Hooke; Cheryl Rodgers; Olga Taylor; Kari M Koerner; Pauline Mitby; Ida Moore; Michael E Scheurer; Wei Pan Journal: J Pain Symptom Manage Date: 2017-04-20 Impact factor: 3.612
Authors: Smita Bhatia; Harland N Sather; Nyla A Heerema; Michael E Trigg; Paul S Gaynon; Leslie L Robison Journal: Blood Date: 2002-09-15 Impact factor: 22.113
Authors: Lauren C Daniel; Raphaele R L van Litsenburg; Valerie E Rogers; Eric S Zhou; Sarah J Ellis; Claire E Wakefield; Robyn Stremler; Lisa Walter; Valerie McLaughlin Crabtree Journal: Psychooncology Date: 2019-11-03 Impact factor: 3.955
Authors: Shosha H M Peersmann; Martha A Grootenhuis; Annemieke van Straten; Gerard A Kerkhof; Wim J E Tissing; Floor Abbink; Andrica C H de Vries; Jacqueline Loonen; Leontien C M Kremer; Gertjan J L Kaspers; Raphaële R L van Litsenburg Journal: Cancers (Basel) Date: 2022-02-13 Impact factor: 6.639